Literature DB >> 22767133

Probable cytarabine-induced acral erythema: report of 2 pediatric cases.

Serap Ozmen1, Mahmut Dogru, Ceyhun Bozkurt, Ayse Ceyda Kocaoglu.   

Abstract

Acral erythema (palmoplantar erythrodysesthesia) is a localized skin side effect that is seen most often in patients receiving cytarabine, liposomal pegylated doxorubicin, capecitabine, and 5-fluorouracil. It is characterized by painful erythema of both palms and soles with symmetrically well-defined borders, which may progress to bullae formation and desquamation. It is frequently occurred in patients with acute myeloid leukemia and lymphoma. Here, we reported 2 cases of acral erythema that developed during cytarabin-etoposide and cytarabine-mitoxantrone combination treatment for acute myeloid leukemia. Although rarely reported in children, pediatricians should especially be aware of this reaction when taking care of children who receive chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22767133     DOI: 10.1097/MPH.0b013e3182580ba0

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.

Authors:  Jose Rodolfo Guerra; Ana M Suelves; Archie Bella; Delatre Lolo
Journal:  BMJ Case Rep       Date:  2014-05-19

2.  Palmar-plantar erythrodysesthesia associated with high-dose methotrexate: Case report.

Authors:  Priyanka Chauhan; Anshul Gupta; Sujeet Kumar; Arijit Bishnu; Soniya Nityanand
Journal:  Cancer Rep (Hoboken)       Date:  2020-08-07

3.  Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.

Authors:  Seth E Karol; Wenjian Yang; Colton Smith; Cheng Cheng; Clinton F Stewart; Sharyn D Baker; John T Sandlund; Jeffrey E Rubnitz; Michael W Bishop; Alberto S Pappo; Sima Jeha; Ching-Hon Pui; Mary V Relling
Journal:  Cancer       Date:  2017-05-11       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.